Basic Information
Development and production of bioconjugate vaccines for bacterial infections using recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugate vaccines for a range of bacterial diseases, such as pneumococcal disease and hospital-acquired infections.
GlycoVaxyn AG
Zurich,Zurich,Switzerland
15~50 people
January 01, 2004
--